Conduit Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing clinical-stage assets that address unmet medical needs. The company concentrates on therapeutic programs in autoimmune diseases and idiopathic male infertility, with research centered on conditions such as Hashimoto’s thyroiditis, uveitis, renal transplant rejection, and preterm labor. Its current pipeline includes assets such as AZD1656 and AZD5904, which are being explored for their potential applications across these treatment areas. Conduit Pharmaceuticals works at the intersection of drug development, clinical research, and asset advancement, aiming to support the progression of novel therapies through the development process. The company is headquartered in Naples, Florida.